Related Experiment Video

Updated: Nov 22, 2025

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
06:04

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome

Published on: September 27, 2024

1.2K

Increased modifiable cardiovascular risk factors in patients with Takayasu arteritis: a multicenter cross-sectional

Alexandre Moura Dos Santos1, Rafael Giovani Misse1, Isabela Bruna Pires Borges1

  • 1Division of Rheumatology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, Brazil.

Advances in Rheumatology (London, England)
|January 9, 2021
PubMed

Insights

Patients with Takayasu arteritis (TAK) show impaired modifiable cardiovascular risk factors (MCRFs), including reduced aerobic capacity and muscle strength. These deficits were not linked to disease activity, suggesting targeted MCRF improvement strategies are needed for TAK management.

Area of Science:

  • Cardiovascular Medicine
  • Rheumatology
  • Exercise Physiology

Background:

  • Modifiable cardiovascular risk factors (MCRFs) are understudied in Takayasu arteritis (TAK).
  • Investigating MCRFs in TAK is crucial for understanding disease impact and management.
  • This study focuses on aerobic capacity, muscle strength, physical activity, and body composition in TAK patients.

Purpose of the Study:

  • To investigate MCRFs in adult women with TAK.
  • To examine the relationship between MCRFs and disease status in TAK.
  • To assess MCRFs in relation to comorbidities in TAK patients.

Main Methods:

  • A multicenter, cross-sectional study comparing 20 women with TAK to 16 healthy controls.
  • Assessment of aerobic capacity, muscle function, muscle strength, body composition, physical activity, and quality of life.
  • Evaluation of disease activity using ITAS2010 and NIH scores, alongside comorbidity assessment.

Main Results:

  • TAK patients exhibited significantly reduced aerobic capacity (VO2 peak), lower limb muscle strength, and poorer walking capacity compared to controls.
  • Increased visceral adipose tissue and waist-to-hip ratio were observed in TAK patients.
  • No significant correlations were found between MCRF parameters and disease activity (ITAS2010/NIH scores).

Conclusions:

  • Takayasu arteritis is associated with significant impairments in modifiable cardiovascular risk factors.
  • These MCRF deficits in TAK patients do not correlate with current disease activity.
  • Intervention strategies aimed at improving MCRFs should be considered in the comprehensive management of Takayasu arteritis.
Abstract

Keywords:
Aerobic capacityCardiovascular diseasesMuscle strengthVasculitis

More Related Videos

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression13:07

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Published on: January 15, 2022

4.2K
A Methodological Approach to Non-invasive Assessments of Vascular Function and Morphology09:33

A Methodological Approach to Non-invasive Assessments of Vascular Function and Morphology

Published on: February 7, 2015

16.6K

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
672
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
136
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
227
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
176
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
126
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
477